Richter's transformation in chronic lymphocytic leukemia

ONCOLOGY (United States)

Volumn 26, Issue 12, 2012, Pages

  Jain, Preetesh ^a   O'Brien, Susan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE; ALEMTUZUMAB; CD38 ANTIGEN; CIDOFOVIR; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN HEAVY CHAIN; LACTATE DEHYDROGENASE; METHYLPREDNISOLONE; MYC PROTEIN; NOTCH1 RECEPTOR; OFATUMUMAB; OXALIPLATIN; PREDNISONE; PROTEIN P53; RITUXIMAB; VINCRISTINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIGEN EXPRESSION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL CYCLE REGULATION; CHROMOSOME ABERRATION; CHRONIC LYMPHATIC LEUKEMIA; CLONAL VARIATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CYTOGENETICS; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DNA POLYMORPHISM; DRUG POTENTIATION; DRUG RESPONSE; ENZYME ACTIVATION; EPSTEIN BARR VIRUS INFECTION; GENE DISRUPTION; HEPATOSPLENOMEGALY; HUMAN; HYPERCALCEMIA; IMMUNOPHENOTYPING; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LYMPHADENOPATHY; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT TRANSFORMATION; PANCYTOPENIA; PATHOGENESIS; PROGNOSIS; PROLYMPHOCYTIC LEUKEMIA; REVIEW; RICHTER SYNDROME; RISK FACTOR; STEREOTYPY; SURVIVAL TIME; THROMBOCYTE COUNT; TUMOR VOLUME;

EID: 84874609184     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446-56.
2. SEER cancer statistics review (1975-2009). Available from: http://seer.cancer.gov/csr/1975_2009_pops09/index.html.
3. Lortholary P, Boiron M, Ripault P, et al. [chronic lymphoid leukemia secondarily associated with a malignant reticulopathy: Richter's syndrome]. Nouv Rev Fr Hematol. 1964;4:621-44.
4. Molica S. A systematic review on Richter syndrome: what is the published evidence? Leuk Lymphoma. 2010;51:415-21.
5. Tsimberidou AM, O'Brien S, Kantarjian HM, et al. Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience. Cancer. 2006;107:1294-302.
6. Bockorny B, Codreanu I Dasanu CA. Hodgkin lymphoma as Richter transformation in chronic lymphocytic leukaemia: a retrospective analysis of world literature. Br J Haematol. 2012;156:50-66.
7. Michelis FV, Kourti G, Skertsou M, et al. Richter transformation of chronic lymphocytic leukemia into composite diffuse large B-cell and Hodgkin lymphoma. Leuk Lymphoma. 2012.
8. Fraser CR, Wang W, Gomez M, et al. Transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma to interdigitating dendritic cell sarcoma: evidence for transdifferentiation of the lymphoma clone. Am J Clin Pathol. 2009;132:928-39.
9. Richter MN. Generalized reticular cell sarcoma of lymph nodes associated with lymphatic leukemia. Am J Pathol. 1928;4:285-92 7.
10. Mao Z, Quintanilla-Martinez L, Raffeld M, et al. IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution. Am J Surg Pathol. 2007;31:1605-14.
11. Rossi D, Spina V, Deambrogi C, et al. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood. 2011;117:3391-401.
12. Melo JV, Catovsky D, Galton DA. The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. II. Patterns of evolution of prolymphocytoid' transformation. Br J Haematol. 1986; 64:77-86.
13. Gine E, Martinez A, Villamor N, et al. Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (accelerated chronic lymphocytic leukemia) with aggressive clinical behavior. Haematologica. 2010;95:1526-33.
14. Tsimberidou AM, O'Brien S, Khouri I, et al. Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol. 2006;24:2343-51.
15. Rossi D, Cerri M, Capello D, et al. Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome. Br J Haematol. 2008;142:202-15.
16. Fan L, Wang L, Zhang R, et al. Richter transformation in 16 of 149 Chinese patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2012;53:1749-56.
17. Timar B, Fulop Z, Csernus B, et al. Relationship between the mutational status of VH genes and pathogenesis of diffuse large B-cell lymphoma in Richter's syndrome. Leukemia. 2004;18:326-30.
18. Tsimberidou AM, Keating MJ, Bueso-Ramos CE, Kurzrock R. Epstein-Barr virus in patients with chronic lymphocytic leukemia: a pilot study. Leuk Lymphoma. 2006;47:827-36.
19. de Leval L, Vivario M, De Prijck B, et al. Distinct clonal origin in two cases of Hodgkin's lymphoma variant of Richter's syndrome associated With EBV infection. Am J Surg Pathol. 2004;28:679-86.
20. Tzankov A, Fong D. Hodgkin's disease variant of Richter's syndrome clonally related to chronic lymphocytic leukemia arises in ZAP-70 negative mutated CLL. Med Hypotheses. 2006;66:577-9.
21. Fangazio M, De Paoli L, Rossi D, Gaidano G. Predictive markers and driving factors behind Richter syndrome development. Expert Rev Anticancer Ther. 2011;11:433-42.
22. Rossi D, Gaidano G. Richter syndrome: molecular insights and clinical perspectives. Hematol Oncol. 2009;27:1-10.
23. Aydin S, Rossi D, Bergui L, et al. CD38 gene polymorphism and chronic lymphocytic leukemia: a role in transformation to Richter syndrome? Blood. 2008;111:5646-53.
24. Rossi D, Rasi S, Spina V, et al. Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome. Br J Haematol. 2012;158:426-9.
25. Solh M, Rai KR, Peterson BL, et al. The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011). Leuk Lymphoma. 2012 Sep 8. [Epub ahead of print]
26. Omoti CE, Omoti AE. Richter syndrome: a review of clinical, ocular, neurological and other manifestations. Br J Haematol. 2008;142:709-16.
27. Bruzzi JF, Macapinlac H, Tsimberidou AM, et al. Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT. J Nucl Med. 2006; 47:1267-73.
28. Ansell SM, Armitage JO. Positron emission tomographic scans in lymphoma: convention and controversy. Mayo Clin Proc. 2012;87:571-80.
29. Moskowitz CH, Schoder H, Teruyua-Feldstein J, et al. Risk-adapted dose-dense immune chemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol. 2010; 28:1896-1903.
30. Abruzzo LV, Rosales CM, Medeiros LJ, et al. Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms. Am J Surg Pathol. 2002;26:630-6.
31. Ansell SM, Li CY, Lloyd RV, Phyliky RL. Epstein-Barr virus infection in Richter's transformation. Am J Hematol. 1999;60:99-104.
32. Dungarwalla M, Matutes E, Dearden CE. Prolymphocytic leukaemia of B-and T-cell subtype: a state-of-the-art paper. Eur J Haematol. 2008;80:469-76.
33. Asano N, Yamamoto K, Tamaru J, et al. Age-related Epstein-Barr virus (EBV)-associated B-cell lymphoproliferative disorders: comparison with EBV-positive classic Hodgkin lymphoma in elderly patients. Blood. 2009;113:2629-36.
34. Louissaint A, Jr., Ferry JA, Soupir CP, et al. Infectious mononucleosis mimicking lymphoma: distinguishing morphological and immunophenotypic features. Mod Pathol. 2012;25:1149-59.
35. Roschewski M Wilson WH. EBV-associated lymphomas in adults. Best Pract Res Clin Haematol. 2012;25:75-89.
36. Tsimberidou AM, O'Brien SM, Cortes JE, et al. Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders. Leuk Lymphoma. 2002;43:767-72.
37. Dabaja BS, O'Brien SM, Kantarjian HM, et al. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome. Leuk Lymphoma. 2001;42:329-37.
38. Tsimberidou AM, Kantarjian HM, Cortes J, et al. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer. 2003;97: 1711-20.
39. Tsimberidou AM, Wierda WG, Plunkett W, et al. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2008;26:196-203.
40. Tsimberidou AM, Wierda WG, Wen S, et al. Results of a phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab (OFAR) combination therapy in patients with aggressive, relapsed/refractory chronic lymphocytic leukemia (CLL) and Richter syndrome (RS). ASH Annual Meeting Abstracts. 2010;116:923.
41. Jenke P, Eichhorst B, Busch R, et al. Cyclophosphamide, adriamycin, vincristine and prednisone plus rituximab (CHOP-R) in fludarabine (F) refractory chronic lymphocytic leukemia (CLL) or CLL with autoimmune cytopenia (AIC) or Richter's transformation (RT): final analysis of a phase II study of the German CLL Study Group. ASH Annual Meeting Abstracts. 2011;118:2860.
42. Tsimberidou AM, Murray JL, O'Brien S, et al. Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome. Cancer. 2004;100:2195-200.
43. Cwynarski K, van Biezen A, de Wreede L, et al. Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syndrome): a retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2012;30:3322-7.